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dverse Outcomes From
he Use of Older Donor Hearts
n Cardiac Transplant Recipients
he Pros and Cons of
xpanded Donor Criteria*
oward J. Eisen, MD, FACC
hiladelphia, Pennsylvania
ardiac transplantation provides definitive therapy for se-
ected patients with end-stage congestive heart failure and
as resulted in improved survival for these patients. Cardiac
ransplantation has also been associated with improving
urvival during the past two decades since it re-emerged as
n important option after the introduction of cyclosporine
n 1983 (1). In particular, the improvements in survival that
ave been noted both in a multi-institutional study and in
he study by Lietz et al. (2) in this issue of the Journal appear
o be the result of several innovations in therapy for cardiac
ransplant recipients (1,2). These include improvements in
mmunosuppressive therapies over the last 15 years, refine-
ents in surgical techniques, and improvement in therapies
o treat or prevent post-transplant infectious diseases (3,4).
See page 1553
hese improvements in survival have occurred despite the
ncreasing use of expanded donor criteria and what have
een termed “marginal donors.” As the donor shortage has
orsened and the number of patients waiting for transplants
as increased, efforts have been made to expand what is
onsidered acceptable in a wide variety of categories related
o the donor (5). Expanded donor criteria include the use of
onors substantially smaller than the recipients, donors with
ut sometimes-obstructive coronary artery disease, left ven-
ricular dysfunction, or donors from older age groups (5).
ndersized hearts have been used successfully with excellent
ong-term outcomes (6). Traditionally, cardiac transplants
ere obtained from donors 35 years in age (7). Perhaps
he greatest area of expansion of the donor population has
een because of the increasing use of hearts from older
onors, including donors older than 40 years of age or even
lder than 50 years of age. Several small single-center
tudies have shown that the use of these donors does not
mpart diminished survival to the recipients (8,9). In con-
rast, a multi-institutional study from the Cardiac Trans-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Advanced Heart Failure and Transplant Center, Temple University
chool of Medicine, Philadelphia, Pennsylvania. Supported by a grant from the
dmerican Heart Association National Center.lant Research Database indicates that the use of donors
lder than 40 years or age is associated with diminished
urvival after cardiac transplantation (2).
To more definitely answer this question, Lietz et al. (2)
etrospectively studied the outcomes of their population of
ardiac transplant recipients at Columbia-Presbyterian Medi-
al Center from 1992 to 1999. Numerous factors related to the
ecipient and donor were studied, including the etiology of
rain death in the donor, the era in which the transplant was
erformed, the United Network for Organ Sharing priority
tatus, the use of left ventricular assist devices before transplant,
ecipient gender, and the age of the recipient and donor.
ost-transplant outcomes studied included survival, acute al-
ograft rejection, and the development of cardiac allograft
asculopathy defined by the presence of a new discrete angio-
raphic lesion 50%, in the proximal or midportions of the
ajor graft vessels or the presence of diffuse concentric nar-
owing of the whole vessels, including the branches. Alterna-
ively, intravascular ultrasound was also used to determine the
resence of increased intimal thickness. The analysis of the
ata showed that there was, in fact, a significant increase in
ortality in cardiac allograft recipients receiving hearts from
onors40 years of age, with the most significant reduction in
urvival due to increased one-month mortality. If one elimi-
ated the patients who died within the first month, however,
here was no difference in long-term survival among the
ecipients of older hearts compared with those who received
earts from younger donors. However, there were more pa-
ients who developed cardiac allograft vasculopathy among the
atients who received hearts from older donors compared with
hose who received hearts from younger donors.
The authors also identified additional risk factors for poor
utcome in the first month after survival, including ischemic
imes 4 h. However, they also concluded that if one
ooked at the survival of recipients who received hearts from
lder donors and compared this with the survival of patients
ho never received transplants, that the mortality was much
igher among those who did not receive a transplant than
or those who received hearts from older donors in the
tatus 1 group, although the same could not be said for the
tatus 2 group. The implication of this finding is that
espite the increased risk of using allografts from older
onors, especially during the first month after transplant,
hat it is still appropriate in selected patients, particularly
hose who are Status 1 before transplant, to use hearts from
lder donors and that this strategy imparted a survival
enefit.
This work has important implications for both the
election of the patients awaiting cardiac transplantation, as
ell as, the post-transplant management strategies for these
atients. In particular, it is apparent that the greatest risk for
sing hearts from older donors is within the first month
fter transplant. Therefore, efforts should be made to reduce
oincident risks. Thus, recipients receiving who are candi-
ates for receiving hearts from older donors should only
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May 5, 2004:1562–4 Editorial Commenteceive these allografts if the ischemic time can be kept to
4 h as a longer ischemic time resulted in an increased risk
or poor outcome.
Unfortunately, the present study provided no clearly
efined predominant etiology for death within the first
onth for those receiving hearts from older donors. The
auses of death, including sepsis, heart failure, hemorrhage,
nd acute rejection, and distribution of causes of death were
imilar between heart recipients of hearts from older donors
nd those of hearts from younger donors. Therefore, ap-
roaches to try to further minimize poor outcomes in
ecipients of hearts from older donors may be hampered by
lack of knowledge at the present time regarding the
elationships of the use of older allografts to the specific
auses of the poor outcomes within the first 30 days after
ransplant. Nonetheless, careful selection of recipients and
onors, including donors at hospitals relatively close to the
ecipient site, may be in order. Older donors at hospitals
lose to the recipient hospital, as well as recipients with less
omorbidity, ideally should be considered to optimize sur-
ival in the recipients of hearts from older donors. More
ggressive efforts to prevent infections in the post-transplant
eriod may also be beneficial to recipients of older-donor
earts. Cardiac allograft rejection by itself was not increased
n recipients of hearts from older donors, and one would not
xpect this to be the case because rejection is determined by
he response of the immune system of the recipient to the
lloantigens of the donor. There is no evidence that hearts
rom older donors are less likely to express alloantigens.
Intriguingly, the development of cardiac allograft vascu-
opathy, generally defined angiographically, was greater in
he recipients of hearts from older donors than in the
ecipients of hearts from younger donors. The relationship
f donor age to the development of cardiac allograft vascu-
opathy has not been clearly defined. There are single-center
tudies that indicate that the risk of this disease is not
ncreased using hearts from older donors, but multi-
nstitutional studies, such as from the Cardiac Transplant
esearch Database (CTRD), have suggested that the risk is
reater for the development of cardiac allograft vasculopathy
n recipients of hearts from older donors (1,8,9). This, in
act, may be a reflection of age-related endothelial dysfunc-
ion, which has been observed in nontransplant recipients.
lthough the present study is also from a single center,
iven the very large size of the patient cohort studied, as well
s the careful statistical analysis, it does appear that this
ork confirms that in the multi-institutional study that
onor age does increase the risk for cardiac allograft
asculopathy. Tuzcu et al. (10) have defined the normal
ntimal thickness using a surrogate marker of adverse
ascular remodeling and endothelial damage in newly trans-
lanted patients. They found that maximal intimal thick-
ess does increase with increasing age of donors as defined
y intravascular ultrasound.
Another potential explanation for the increased likeli-ood of development of cardiac allograft vasculopathy is thetiology of brain death in the donor. Mehra et al. (11) have
hown that more explosive causes of brain death may result
n significant damage to the heart while in the donor and
hat this may result in endothelial damage and subsequently
n cardiac allograft vasculopathy. If one looks at the etiology
f brain death in the donors, in fact, head trauma, which
ould be a more abrupt cause of brain death, was less likely
o occur in donors older than 40 years of age. This indicates
hat this potential mechanism would not be operative as a
ause for the increases in cardiac allograft vasculopathy in
hose receiving donor hearts from older patients. The fact
hat cardiac allograft vasculopathy did not increase past the
rst year after transplant is not entirely surprising because
everal investigators have shown that most of the develop-
ent of allograft vasculopathy is within the first years after
ransplant (12).
It is clear that these potential risks in older donors should
ot in any way dissuade transplant cardiologists and sur-
eons from using these hearts in sick Status 1 patients
ecause the survival using these hearts is still significantly
etter than if these patients are allowed to wait longer on the
ransplant list or, in fact, if they make it to transplant. There
s a potential problem with this analysis in that there may be
dditional reasons that would prevent patients from under-
oing cardiac transplantation, such as intermittent episodes
f infections or other comorbidities, and that the population
hat was not transplanted may, in fact, have contributors to
heir poor mortality that transplantation alone may not have
lleviated. Nonetheless, the use of these hearts in appropri-
tely selected patients who are critically ill and are Status 1
ould certainly be indicated. In contrast, the use of hearts
rom older donors does not appear to be improve survival in
he less sick patients, such as the Status 2 patients, and
herefore cannot really be justified. In fact, one can argue
hat using these hearts should be reserved for the sicker
opulations, such as the Status 1 patients, who are at higher
isk of poor outcomes.
Furthermore, efforts should be made to minimize addi-
ional risks, such as reducing donor ischemic time, by using
ore local donors in these selected patients and aiming for
limination of other comorbidities. It is possible that even
onger follow-up on the order of a decade or more might
ave revealed increased major adverse cardiac events and
iminished survival as the result of this increase in cardiac
ransplant vasculopathy. The fact that angiography was used
o define the disease does raise some questions as to
hether, in fact, the extent of disease both in the patients
eceiving the older donor hearts and those who received
ounger donor hearts may in fact have underestimated the
isease. If intravascular ultrasound was used routinely, this
ight have either shown a greater difference between the
ecipients of older-donor hearts and those of younger-donor
earts. This would appear to be likely in light of the results
egarding the presence of increased maximal intimal thick-
ess in older-donor hearts just after transplant.
The newer therapies available to prevent rejection are
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Editorial Comment May 5, 2004:1562–4roliferation or mammalian target of rapamycin (mTOR)
nhibitors, which have been associated with reduction in both
ncidence and severity of cardiac allograft vasculopathy as
etermined intravascular ultrasound one year after transplant
13). This may offer the opportunity to potentially reduce the
xtent of cardiac allograft vasculopathy and would particularly
eneficial to patient populations at higher risk for the devel-
pment of cardiac allograft vasculopathy, such as those who
eceive hearts from older donors. This would be a patient
opulation that should be started early on with mTOR
nhibitors, such as sirolimus or everolimus.
There are several unanswered questions that remain
egarding the outcomes of using hearts from older donors.
n particular, the exact relationship of using older-donor
earts to the poor survival observed within the first month
fter transplant is still not clearly defined. Furthermore, the
xact extent of the cardiac allograft vasculopathy is not
nown because intravascular ultrasound was not used to
efine the presence of cardiac allograft vasculopathy. In
ddition, the fact that cardiac allograft vasculopathy was not
ssociated with an increase in mortality beyond the first 30
ays after transplant raises the question as to whether the
xtent of cardiac allograft vasculopathy has any relationship
s defined in the study to major adverse cardiac events or is
purely an epiphenomenon. These answers will have to wait
urther studies using intravascular ultrasound as well as the
ewer immunosuppressive agents and efforts to minimize
otential comorbidities that can diminish survival in the
arly post-transplant period.
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